A Phase 1 Study to GEC255 Oral Tablets in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Status:
Recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
The overall objective of this Phase 1 study is to evaluate the safety, PK, and anti-tumor
activity of daily oral dosing with GEC255 tablets in subjects with advanced solid tumor with
KRAS p.G12C mutation. To recommend the RP2D based on assessments of multiple dose escalation
and expansion in target cohorts.